
    
      The study consists of two parts: Part 1 (ascending intravenous dose) and Part 2 (ascending
      subcutaneous dose). Subjects will participate in either Part 1 or Part 2. Subjects in Part 1
      and Part 2 will have a residential period of 6 days followed by outpatient visits.
    
  